# NovImmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novimmune

- Industry: Pharmaceuticals
- Headquarters: Geneva, Switzerland
- Website: www.novimmune.com
- Total disclosed funding: $188M
- Latest round: Series B (Feb 18, 2014)
- Investors on record: 10

## About

NovImmune SA is a biotechnology company focused on developing innovative monoclonal antibody therapies for autoimmune diseases and immune-mediated conditions.Founded in 1998 and headquartered in Geneva, Switzerland, NovImmune SA specializes in the research and development of monoclonal antibodies. The company has completed a total of 9 deals, with the most recent investment round in January 2016, raising CHF 30 million from existing investors. The current CEO is Nicolas Fischer.NovImmune SA specializes in innovative biotechnology solutions, particularly in monoclonal antibody development aimed at treating autoimmune diseases and immune-mediated conditions. Their core offerings include advanced therapeutic products that address complex immune system challenges, providing targeted treatments to improve patient outcomes.The revenue model for NovImmune SA is primarily based on partnership agreements and direct sales of its therapeutic products, structured around annual or multi-year contracts. This allows for a steady income stream as clients utilize their comprehensive suite of therapeutic solutions. Their flagship products are designed to meet the needs of healthcare providers globally, ensuring a consistent revenue generation framework.NovImmune SA plans to utilize the CHF 30 million raised in January 2016 to further develop its pipeline of monoclonal antibodies. The company is focusing on launching new therapeutic products aimed at expanding its market reach in Europe and North America by 2025. Additionally, NovImmune aims to strengthen its presence in Asia through strategic partnerships with local healthcare providers.

## Funding rounds

- Series B, Feb 18, 2014, $67M — Rosetta Capital
- Series B, Nov 1, 2006, $46M — Aravis, Novartis Venture Fund, Lombard Odier Asset Management, BZ Bank, Pictet Alternative Advisors
- Series C, Jun 1, 2006, $53M — Akina, Aravis, Novartis Venture Fund, Pictet Group, BZ Bank, Varuma, Ingro Finanz
- Series B, Feb 1, 2005, $13M — Akina, Aravis, Novartis Venture Fund, Pictet Group, BZ Bank
- Series A, May 1, 2000, $9M — Akina, Novartis Venture Fund

## Investors

- Akina (https://capitalatlas.ai/funds/akina) — Series A, Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B, Series C
- Aravis (https://capitalatlas.ai/funds/aravis) — Series B, Series C
- Pictet Group — Series B, Series C
- BZ Bank — Series B, Series C
- Varuma — Series C
- Ingro Finanz — Series C
- Lombard Odier Asset Management — Series B
- Pictet Alternative Advisors (https://capitalatlas.ai/funds/pictet-alternative-advisors) — Series B
- Rosetta Capital (https://capitalatlas.ai/funds/rosetta-capital) — Series B